Clinical Genomics appoints Tadd Lazarus, MD, as Chief Medical Officer
BRIDGEWATER, N.J., Jan. 18, 2018
Clinical Genomics, a leading provider of cancer diagnostic solutions and liquid biopsy tests, today announced the appointment of Tadd Lazarus, M.D., as Chief Medical Officer. Lazarus joins the organization as an experienced Chief Medical Officer with over 20 years in the biotechnology and IVD industries and a strong background in clinical trials, regulatory affairs and medical advocacy.
“We are extremely pleased to welcome Dr. Lazarus to the Clinical Genomics team and are looking forward to gaining the benefit of his clinical expertise and passionate patient advocacy as we strive towards our company goals,” said Lawrence LaPointe, PhD, CEO of Clinical Genomics.
“I am very excited to be a part of Clinical Genomics – the leader in both the screening and monitoring of colorectal cancer. The combination of our innovative products will continue to be instrumental in reducing both the morbidity and mortality of this disease,” added Dr. Lazarus.
Prior to joining Clinical Genomics, Lazarus was most recently Sr. Vice President and Chief Medical Officer for Luminex, focusing on the strategic clinical direction for the company. He served as Chief Medical and Head of Medical & Scientific Affairs, Reimbursement, and Public Policy at Qiagen from 2013 through 2016. In 2010, Lazarus was at Gen-Probe Inc., (now Hologic), as Chief Medical Officer and VP of Clinical Affairs, where he was responsible for a 42-person team dedicated to clinical trials. Lazarus began his career at Roche Diagnostics, where he held simultaneous roles in private practice and as Director of Medical and Scientific Affairs, and then as the North American Medical Director for the molecular diagnostics, POC, diabetes, clinical chemistry, and immunology lines of business.
Lazarus received a Bachelor of Science in Biology & Physiology from Marlboro College, and earned his Medical Degree from Ross University School of Medicine.
About Clinical Genomics
Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, including InSure® FIT™, a fecal immunochemical test for screening in healthy adults, to COLVERA™, a proprietary liquid biopsy test identifying circulating tumor DNA in patient’s post-treatment for early detection of recurrence and residual disease. Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management. Clinical Genomics continues to apply its proprietary innovation in molecular pathology to commercialize other diagnostic tools in other cancer types.